The Vision business at Johnson & Johnson MedTech has hit its latest milestone, earning a significant regulatory nod for its ...

Study met primary endpoint of ≥15-letter (≥3-line) gain in mesopic low contrast distance visual acuity in comparison to placebo Phase 3 study showed patient-reported functional benefit in treating ...

MR-142 Achieved Primary Endpoint of ≥15-letter (≥3-line) Gain in Mesopic Low Contrast Distance Visual Acuity in Comparison to Placebo Results Showed Patient-Reported Functional Benefit in Treating ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Multifocal and single vision lenses performed similarly ...

The new, full-range TECNIS Odyssey intraocular lens aims to reduce dependence on glasses, with strong performance in any ...